Good news to finish the week on: I thought you... - MPN Voice

MPN Voice

10,886 members15,202 posts

Good news to finish the week on

Ovingite profile image
7 Replies

I thought you might be interested to see this article from the British Society for Hematology, published earlier this week. It seems that there is active research into MPN across many parts of the world - which is great for us.

On a personal note I also homed in on the third para which states definitively that MPNs are chronic cancers - I might just mention to my hemo consultant (who is a cancer denier) that the BSH has a different view ;-o . Whatever you call MPN's, this is good news that gives more hope for the future.

John

==============================================================

British researchers have developed a new tool which they believe will improve prediction of prognosis for patients with myeloproliferative neoplasms.

The tool combines extensive genetic and clinical information, and identifies eight genetic sub-groups linked to patterns of clinical disease and patient prognosis, the researchers reported in the New England Journal of Medicine last week.

Myeloproliferative neoplasms are a group of blood cancers affecting around 30,000 patients in the UK. These cancers are chronic, long-term conditions and patients suffer from a risk of blood clots and bleeding. In addition, these cancers can progress to more advanced forms of disease, including acute leukaemia, that have a poor outlook.

Currently, myeloproliferative neoplasms are divided into three clinical types, in a system dating from the 1950s. However, it is known that this classification system can’t give an accurate prognosis for individual patients, making it difficult for doctors to decide on the most appropriate course of treatment.

The researchers from the Wellcome Sanger Institute, the Wellcome-MRC Cambridge Stem Cell Institute and Cambridge University sequenced 69 cancer genes in cancerous cells from more than 2,000 patients.

Combining this with clinical information, they developed a prognostic tool which outperformed existing classification systems. It had the added benefit of giving personalised predictions for individual patients, rather than assigning patients to broad risk groups.

Co-leader of the study Professor Tony Green, from the Wellcome-MRC Cambridge Stem Cell Institute, said: “This work represents a step change in our understanding of the myeloproliferative neoplasms. Not only does it reveal a new classification based on causal mechanisms but it also provides for the first time personally-tailored predictions to guide patient management.”

Co-first author Dr Jyoti Nangalia, from the Wellcome Sanger Institute, said: “Despite some knowledge of the risks of myeloproliferative neoplasms we have been unable to make accurate personal predictions for individual patients.

“Our new online calculator takes genetic and clinical information available for a patient and makes a prediction of the future outcome of that particular person’s disease.”

Source: b-s-h.org.uk/about-us/news/... dated 15 Oct 2018

Written by
Ovingite profile image
Ovingite
To view profiles and participate in discussions please or .
Read more about...
7 Replies
Superwoman profile image
Superwoman

Hi John thanks for that, good article.

Jean

nightssky profile image
nightssky

a good find well done the is for posting I'm sure many will find this a very interesting read as I did good work Ovingite as usual 5 *

MPort profile image
MPort

Hi, thanks for posting this. I am very pleased to read of this new way to identifying and then tailoring treatment. It is very encouraging.

Mairead

Wyebird profile image
Wyebird

Thank you it was an easy read

Johnsb profile image
Johnsb

Thks for posting! I have previously downloaded the full report in hopes having the time to digest it. I think it is worth a brief scan by all of us. I think Max posted the link a while back. It is very clinical but worth the scan.

ansaseeker profile image
ansaseeker

Hi Ovingite,thank you for the very informative post.As we are all individuals we all do need specific treatment. I welcome the genome testing.It can only be good for us and we do deserve the very best, always.Best wishes Marilyn.x

ksos profile image
ksos

Thanks, Ovingte, for posting. Very helpful. I also downloaded the full report and found a lot in it, but, understandably, my friends and family don't have the same kind of interest in the details that I do :) Having this, which gives a cogent summary of the most important points, is perfect on those occasions when they ask for information.

Kim

Not what you're looking for?

You may also like...

Cancer Research UK - Information regarding MPN's

Hi All I may be passing on something that you all already know about - but just in case thought I...
amarylis profile image

Guidelines Myeloproliferative Neoplasms and Articles of Interest

Hello I have listed some links for MPN articles of interest. Kind regards Anna The 2016 revision to...

Simple Tree for MPN Classification Via the 'Machine-Learning Model' – ML

Post by MPN-MATE Admin » Thu Nov 07, 2024 10:21 am Morning everyone... I recently received this...
socrates_8 profile image

Immunotherapy, early research for Jak2

We care about immune therapy because it's potentially curative by teaching our immune system to...
EPguy profile image

2022 NCCN Guidelines for MPNs

Another good resource posted by our friends from the MPN Research Foundation. 2022 National...
hunter5582 profile image

Moderation team

Debinha profile image
DebinhaAdministrator
Mazcd profile image
MazcdPartner

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.